Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines.
Recombinant viruses based on modified vaccinia virus Ankara (MVA) are vaccine candidates against infectious diseases and cancers. Presently, multiplication of MVA has been demonstrated in chicken embryo fibroblast and baby hamster kidney (BHK-21) cells only. The multiplication and morphogenesis of a recombinant (MVA-HANP) and non-recombinant MVA strain in BHK-21 and 12 other mammalian cell lines have now been compared. Rat IEC-6 cells were fully permissive to MVA infection. The virus yield in IEC-6 cells was similar to that obtained in BHK-21 cells at low as well as high multiplicities of infection. Vero cells were semi-permissive to MVA infection. Mature virions were produced in supposedly non-permissive cell lines. The multiplication and morphogenesis of non-recombinant MVA and MVA-HANP were similar. These results are relevant to the production and biosafety of MVA-vectored vaccines.
Okeke
Malachy Ifeanyi
MI
Department of Microbiology and Virology, Faculty of Medicine, University of Tromsø, N-9037 Tromsø, Norway.
Nilssen
Øivind
Ø
Department of Medical Genetics, University Hospital of North Norway, N-9038 Tromsø, Norway.
Traavik
Terje
T
GENOK-Norwegian Institute of Gene Ecology, Tromsø Science Park, N-9294 Tromsø, Norway.|Department of Microbiology and Virology, Faculty of Medicine, University of Tromsø, N-9037 Tromsø, Norway.
D000818:Animals; D002460:Cell Line; D002461:Cell Line, Transformed; D002522:Chlorocebus aethiops; D006224:Cricetinae; D004279:DNA, Viral / Q000378:metabolism; D007668:Kidney; D051381:Rats; D014616:Vaccinia virus / Q000254:growth & development / Q000502:physiology*; D014709:Vero Cells; D014771:Virion / Q000502:physiology*; D014779:Virus Replication
D004279:DNA, Viral